Rare subclonal sequencing of breast cancers indicates putative metastatic driver mutations are predominately acquired after dissemination

被引：0
|
作者：
Matthew R. Lawrence-Paul
Tien-chi Pan
Dhruv K. Pant
Natalie N. C. Shih
Yan Chen
George K. Belka
Michael Feldman
Angela DeMichele
Lewis A. Chodosh
机构：
[1] 2-PREVENT Translational Center of Excellence,Department of Cancer Biology
[2] Abramson Family Cancer Research Institute,Department of Pathology & Laboratory Medicine
[3] Perelman School of Medicine at the University of Pennsylvania,Department of Medicine
[4] Perelman School of Medicine at the University of Pennsylvania,Department of Biostatistics, Epidemiology and Informatics
[5] Perelman School of Medicine at the University of Pennsylvania,undefined
[6] Perelman School of Medicine at the University of Pennsylvania,undefined
来源：
Genome Medicine | / 16卷
关键词：
Breast cancer; Metastasis; Rare subclonal sequencing; Ultra-deep sequencing; Genomics; Metastatic driver mutation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 12 条
  • [1] Rare subclonal sequencing of breast cancers indicates putative metastatic driver mutations are predominately acquired after dissemination
    Lawrence-Paul, Matthew R.
    Pan, Tien-chi
    Pant, Dhruv K.
    Shih, Natalie N. C.
    Chen, Yan
    Belka, George K.
    Feldman, Michael
    Demichele, Angela
    Chodosh, Lewis A.
    GENOME MEDICINE, 2024, 16 (01)
  • [2] Integrative analysis of mutational and transcriptional profiles reveals driver mutations of metastatic breast cancers
    Lee, Ji-Hyun
    Zhao, Xing-Ming
    Yoon, Ina
    Lee, Jin Young
    Kwon, Nam Hoon
    Wang, Yin-Ying
    Lee, Kyung-Min
    Lee, Min-Joo
    Kim, Jisun
    Moon, Hyeong-Gon
    In, Yongho
    Hao, Jin-Kao
    Park, Kyung-Mii
    Noh, Dong-Young
    Han, Wonshik
    Kim, Sunghoon
    CELL DISCOVERY, 2016, 2
  • [3] Integrative analysis of mutational and transcriptional profiles reveals driver mutations of metastatic breast cancers
    Ji-Hyun Lee
    Xing-Ming Zhao
    Ina Yoon
    Jin Young Lee
    Nam Hoon Kwon
    Yin-Ying Wang
    Kyung-Min Lee
    Min-Joo Lee
    Jisun Kim
    Hyeong-Gon Moon
    Yongho In
    Jin-Kao Hao
    Kyung-Mii Park
    Dong-Young Noh
    Wonshik Han
    Sunghoon Kim
    Cell Discovery, 2
  • [4] Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer
    Park, Yeon Hee
    Shin, Hyun-Tae
    Jung, Hae Hyun
    Choi, Yoon-La
    Ahn, TaeJin
    Park, Kyunghee
    Lee, Aeri
    Do, In-Gu
    Kim, Ji-Yeon
    Ahn, Jin Seok
    Park, Woong-Yang
    Im, Young-Hyuck
    ONCOTARGET, 2015, 6 (31) : 32027 - 32038
  • [5] Genetic heterogeneity and distinct driver mutations in synchronous primary and metastatic breast cancers from therapy-naive patients
    Ng, Charlotte K. Y.
    Bidard, Francois-Clement
    Piscuoglio, Salvatore
    Lim, Raymond S.
    Pierga, Jean-Yves
    Cottu, Paul
    Vincent-Salomon, Anne
    Viale, Agnes
    Norton, Larry
    Sigal, Brigitte
    Weigelt, Britta
    Reis-Filho, Jorge S.
    CANCER RESEARCH, 2015, 75
  • [6] Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers
    Muller, Kristen E.
    Marotti, Jonathan D.
    de Abreu, Francine B.
    Peterson, Jason D.
    Miller, Todd W.
    Chamberlin, Mary D.
    Tsongalis, Gregory J.
    Tafe, Laura J.
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2016, 100 (03) : 421 - 425
  • [7] Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer
    Medford, Arielle J.
    Dubash, Taronish D.
    Juric, Dejan
    Spring, Laura
    Niemierko, Andrzej
    Vidula, Neelima
    Peppercorn, Jeffrey
    Isakoff, Steven
    Reeves, Brittany A.
    LiCausi, Joseph A.
    Wesley, Benjamin
    Malvarosa, Giuliana
    Yuen, Megan
    Wittner, Ben S.
    Lawrence, Michael S.
    Iafrate, A. John
    Ellisen, Leif
    Moy, Beverly
    Toner, Mehmet
    Maheswaran, Shyamala
    Haber, Daniel A.
    Bardia, Aditya
    NPJ PRECISION ONCOLOGY, 2019, 3 (1)
  • [8] Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer
    Arielle J. Medford
    Taronish D. Dubash
    Dejan Juric
    Laura Spring
    Andrzej Niemierko
    Neelima Vidula
    Jeffrey Peppercorn
    Steven Isakoff
    Brittany A. Reeves
    Joseph A. LiCausi
    Benjamin Wesley
    Giuliana Malvarosa
    Megan Yuen
    Ben S. Wittner
    Michael S. Lawrence
    A. John Iafrate
    Leif Ellisen
    Beverly Moy
    Mehmet Toner
    Shyamala Maheswaran
    Daniel A. Haber
    Aditya Bardia
    npj Precision Oncology, 3
  • [9] Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A kinase anchoring protein family (AKAPs)
    Kjallquist, U.
    Erlandsson, R.
    Hartman, J.
    Alkodsi, A.
    Tobin, N.
    Hatschek, T.
    Bergh, J.
    Linnarsson, S.
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : S130 - S130
  • [10] Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs)
    Kjallquist, Una
    Erlandsson, Rikard
    Tobin, Nicholas P.
    Alkodsi, Amjad
    Ullah, Ikram
    Stalhammar, Gustav
    Karlsson, Eva
    Hatschek, Thomas
    Hartman, Johan
    Linnarsson, Sten
    Bergh, Jonas
    BMC CANCER, 2018, 18
12